LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)
NCT ID: NCT04889404
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
130 participants
OBSERVATIONAL
2021-05-22
2025-02-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer
NCT00055250
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
NCT01505530
A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
NCT03301805
Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
NCT02289898
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
NCT02184195
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This investigation will be conducted for application for re-examination specified in Article 14-4 of the Pharmaceutical Affairs Law.
\*1: Bone marrow depression, interstitial lung disease, new primary malignancies, and embryofoetal toxicity
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Toshimitsu Tokimoto
Role: STUDY_DIRECTOR
Astrazeneca KK
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Osaka, Lyn010001, Japan
Research Site
Kanagawa, Lyn010003, Japan
Research Site
Okayama, Lyn010004, Japan
Research Site
Akita, Lyn010005, Japan
Research Site
Niigata, Lyn010006, Japan
Research Site
Shizuoka, Lyn010007, Japan
Research Site
Niigata, Lyn010008, Japan
Research Site
Tokyo, Lyn010009, Japan
Research Site
Saitama, Lyn010010, Japan
Research Site
Aichi, Lyn010011, Japan
Research Site
Osaka, Lyn010012, Japan
Research Site
Tokyo, Lyn010013, Japan
Research Site
Nara, Lyn010014, Japan
Research Site
Wakayama, Lyn010015, Japan
Research Site
Miyagi, Lyn010016, Japan
Research Site
Tokyo, Lyn010017, Japan
Research Site
Osaka, Lyn010018, Japan
Research Site
Gunma, Lyn010019, Japan
Research Site
Hiroshima, Lyn010020, Japan
Research Site
Tochigi, Lyn010021, Japan
Research Site
Numakunai, Lyn010022, Japan
Research Site
Osaka, Lyn010025, Japan
Research Site
Shizuoka, Lyn010026, Japan
Research Site
Nagasaki, Lyn010027, Japan
Research Site
Kumamoto, Lyn010028, Japan
Research Site
Saitama, Lyn010029, Japan
Research Site
Nagano, Lyn010031, Japan
Research Site
Hyōgo, Lyn010032, Japan
Research Site
Shimane, Lyn010033, Japan
Research Site
Hyōgo, Lyn010034, Japan
Research Site
Shizuoka, Lyn010035, Japan
Research Site
Hyōgo, Lyn010036, Japan
Research Site
Okayama, Lyn010038, Japan
Research Site
Fukuoka, Lyn010041, Japan
Research Site
Hokkaido, Lyn010042, Japan
Research Site
Ehime, Lyn010044, Japan
Research Site
Osaka, Lyn010045, Japan
Research Site
Shizuoka, Lyn010047, Japan
Research Site
Tokyo, Lyn010050, Japan
Research Site
Aichi, , Japan
Research Site
Chiba, , Japan
Research Site
Fukuoka, , Japan
Research Site
Gunma, , Japan
Research Site
Hiroshima, , Japan
Research Site
Hokkaido, , Japan
Research Site
Hyōgo, , Japan
Research Site
Ibaraki, , Japan
Research Site
Kagawa, , Japan
Research Site
Kanagawa, , Japan
Research Site
Kyoto, , Japan
Research Site
Nagano, , Japan
Research Site
Nagasaki, , Japan
Research Site
Nara, , Japan
Research Site
Okayama, , Japan
Research Site
Osaka, , Japan
Research Site
Shizuoka, , Japan
Research Site
Tokyo, , Japan
Research Site
Tottori, , Japan
Research Site
Toyama, , Japan
Research Site
Yamagata, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D081FC00004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.